South Korean manufacturers of diagnostic kits (rapid tests) for detecting the COVID-19 virus are busy preparing shipments of their products.
Encouraged by the business boom, pharmaceutical manufacturers have jumped into the fray, believing that global demand for COVID-19 test kits will continue to expand this year as well.
On January 21, Humasis announced in a public report that it had agreed with Celltrion to supply them with COVID-19 antigen tests. The deal is worth 4.32 billion won (USD 3.9 million), equivalent to 47.25 percent of Humasis’s revenue in 2019.
You can read the full article at:
Source: KBR (http://www.koreabiomed.com)